FACULTY
Kristle Lee Lynch, MD
Associate Professor of Clinical Medicine
Director, Esophagology and Swallowing Center
Director, Advanced Esophageal Fellowship
Director, Advanced Physiology Laboratory
Division of Gastroenterology
The University of Pennsylvania
Philadelphia, PA
FEATURING
Amanda
Ringoes, NJ
PROGRAM OVERVIEW
This educational activity is designed to help healthcare providers who treat patients with eosinophilic esophagitis (EoE) to better understand the pathophysiology of the disease and to more easily recognize the symptoms of EoE. This program will also examine currently approved and emerging treatments for EoE, as well as the importance of team-based care to improve patient outcomes.
TARGET AUDIENCE
This activity is designed to meet the educational needs of pediatricians and additional primary care providers, as well as their clinical teams.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize key characteristics of EoE pathophysiology
- Assess the clinical signs and symptoms that should arouse suspicion of EoE in the primary care setting
- Interpret results from studies of newly approved and emerging therapeutic options for EoE
- Enhance the quality of patient care through effective collaboration with additional HCPs
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Kristle Lee Lynch, MD | Consulting fees: Medtronic and Regeneron Advisory Board: Phathom Pharmaceuticals and Takeda |
| Amanda (patient) | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- Michael Milano, MD, discloses Up-To-Date royalties from Wolters Kluwer.
- Surabhi Dangi-Garimella, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: July 31, 2024
EXPIRATION DATE: July 31, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Nirmala Gonsalves, MD, AGAF, FACG
Professor of Medicine
Division of Gastroenterology & Hepatology
Co-Director, Northwestern Eosinophilic Gastrointestinal Disorders Program
Northwestern University
The Feinberg School of Medicine
Chicago, IL
PROGRAM FACULTY
Donald K. Brown, MD
Lurie Children’s Hospital of Chicago
Clinical Instructor of Pediatrics
Northwestern University
Feinberg School of Medicine
Chicago, IL
Joshua B. Wechsler, MD, MSCI
Campaign Urging Research for Eosinophilic Disorders (CURED) Foundation Research Scholar
Medical Director, Eosinophilic Gastrointestinal Diseases Program
Assistant Professor of Pediatrics, Gastroenterology, Hepatology and Nutrition
Ann & Robert H. Lurie Children’s Hospital of Chicago
Northwestern University
Chicago, IL
FEATURING
Cormac, Jennifer, and Cameron
Chicago, IL
PROGRAM OVERVIEW
This educational activity is designed to help healthcare providers, especially pediatric specialists, who treat patients with eosinophilic esophagitis (EoE) to better understand the pathophysiology of the disease and to more easily recognize the symptoms of EoE. This program will also examine currently approved and emerging treatments for EoE, as well as the importance of team-based care to improve patient outcomes.
TARGET AUDIENCE
This activity is designed to meet the educational needs of pediatricians and additional primary care providers, as well as their clinical teams.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize key characteristics of EoE pathophysiology
- Assess the clinical signs and symptoms that should arouse suspicion of EoE in the primary care setting
- Interpret results from studies of newly approved and emerging therapeutic options for EoE
- Enhance the quality of patient care through effective collaboration with additional HCPs
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.75 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Nirmala Gonsalves, MD, AGAF, FACG | Royalties: UpToDate Consulting fees: AstraZeneca, Bristol Myers Squibb, Sanofi, Regeneron, Inc., Takeda, Exact Sciences, NexEos Bio Speakers Bureau: Sanofi, Regeneron, Inc., Takeda |
| Donald K. Brown, MD | Has nothing to disclose. |
| Joshua B. Wechsler, MD, MSCI | Consulting fees: Allakos, AstraZeneca, Bristol Myers Squibb, Celldex Therapeutics, Inc., Ellodi Pharmaceuticals, Regeneron, Inc., Sanofi Speakers Bureau: Regeneron, Inc., and Sanofi Contracted research: Clinical trial – Allakos, Regeneron, Inc., and Sanofi |
| Cormac, Jennifer, and Cameron (patient/parents) | Have nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Dominique Barton, BSN, has nothing to disclose.
- Michael Milano, MD, discloses UpToDate royalties from Wolters Kluwer.
- Surabhi Dangi-Garimella, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: September 06, 2024
EXPIRATION DATE: September 06, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
